Cargando…
Pharmacoeconomic Analysis of Fixed-Dose Combinations of Proton Pump Inhibitors Available in India
Introduction The global proton pump inhibitors (PPIs) market was valued at US$ 2.9 billion in 2020 and is expected to exhibit a compound aggregated growth rate of 4.30% during the forecast period (2020-2027), as they are regularly prescribed for many gastrointestinal disorders, and the treatment usu...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10098438/ https://www.ncbi.nlm.nih.gov/pubmed/37065352 http://dx.doi.org/10.7759/cureus.36112 |
_version_ | 1785024810300997632 |
---|---|
author | Deolekar, Pradnya Vivek, Kavita Ghosh, Souvik Naseem, Azra Srivathsan, Mayakalyani Rai, Vivek S Signapurkar, Sonal Yadav, Pramila |
author_facet | Deolekar, Pradnya Vivek, Kavita Ghosh, Souvik Naseem, Azra Srivathsan, Mayakalyani Rai, Vivek S Signapurkar, Sonal Yadav, Pramila |
author_sort | Deolekar, Pradnya |
collection | PubMed |
description | Introduction The global proton pump inhibitors (PPIs) market was valued at US$ 2.9 billion in 2020 and is expected to exhibit a compound aggregated growth rate of 4.30% during the forecast period (2020-2027), as they are regularly prescribed for many gastrointestinal disorders, and the treatment usually lasts for a longer period. PPIs are usually combined with antiemetics and prokinetic drugs. The price of PPIs for the same combination varies a lot, which can lead to a lot of financial burden on the patients. Objective To evaluate the cost ratio and percentage cost variation of commonly used PPIs in various combinations. Methodology The cost of different brands of commonly used PPIs in combination with other drugs was analyzed in our study. A total of 21 different combinations (10 capsules/tablets for oral use) were tabulated by referring to the “Monthly Index of Medical Specialities” October-December 2021, and 1mg online pharmacy. The cost ratio and percentage cost variation for various brands of a particular strength and dosage form were calculated and compared. Cost ratio > 2 and cost variation > 100% were considered significant. Results The results show a huge variation (1788.88%) in costs of different brands with the highest being rabeprazole 20 mg and domperidone 10 mg (cost ratio: 18.88, percentage cost variation: 1788.88%) in oral formulation, followed by pantoprazole 40 mg and itopride 150 mg. The minimum cost ratio (1.35) and percentage cost variation (1.35%) is for pantoprazole 40 mg and levosulpiride 75 mg. Logistic regression analysis between the number of brands and percentage cost variation gives an R(2) value of 0.0923. Conclusion There is a wide variation in the prices of PPIs available in the market, which can inadvertently increase the financial burden of therapy on patients. Physicians need to be made aware of these price differences so that they can choose the best available alternative for patients, which can help in increasing compliance with the prescribed drugs. |
format | Online Article Text |
id | pubmed-10098438 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Cureus |
record_format | MEDLINE/PubMed |
spelling | pubmed-100984382023-04-14 Pharmacoeconomic Analysis of Fixed-Dose Combinations of Proton Pump Inhibitors Available in India Deolekar, Pradnya Vivek, Kavita Ghosh, Souvik Naseem, Azra Srivathsan, Mayakalyani Rai, Vivek S Signapurkar, Sonal Yadav, Pramila Cureus Emergency Medicine Introduction The global proton pump inhibitors (PPIs) market was valued at US$ 2.9 billion in 2020 and is expected to exhibit a compound aggregated growth rate of 4.30% during the forecast period (2020-2027), as they are regularly prescribed for many gastrointestinal disorders, and the treatment usually lasts for a longer period. PPIs are usually combined with antiemetics and prokinetic drugs. The price of PPIs for the same combination varies a lot, which can lead to a lot of financial burden on the patients. Objective To evaluate the cost ratio and percentage cost variation of commonly used PPIs in various combinations. Methodology The cost of different brands of commonly used PPIs in combination with other drugs was analyzed in our study. A total of 21 different combinations (10 capsules/tablets for oral use) were tabulated by referring to the “Monthly Index of Medical Specialities” October-December 2021, and 1mg online pharmacy. The cost ratio and percentage cost variation for various brands of a particular strength and dosage form were calculated and compared. Cost ratio > 2 and cost variation > 100% were considered significant. Results The results show a huge variation (1788.88%) in costs of different brands with the highest being rabeprazole 20 mg and domperidone 10 mg (cost ratio: 18.88, percentage cost variation: 1788.88%) in oral formulation, followed by pantoprazole 40 mg and itopride 150 mg. The minimum cost ratio (1.35) and percentage cost variation (1.35%) is for pantoprazole 40 mg and levosulpiride 75 mg. Logistic regression analysis between the number of brands and percentage cost variation gives an R(2) value of 0.0923. Conclusion There is a wide variation in the prices of PPIs available in the market, which can inadvertently increase the financial burden of therapy on patients. Physicians need to be made aware of these price differences so that they can choose the best available alternative for patients, which can help in increasing compliance with the prescribed drugs. Cureus 2023-03-14 /pmc/articles/PMC10098438/ /pubmed/37065352 http://dx.doi.org/10.7759/cureus.36112 Text en Copyright © 2023, Deolekar et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Emergency Medicine Deolekar, Pradnya Vivek, Kavita Ghosh, Souvik Naseem, Azra Srivathsan, Mayakalyani Rai, Vivek S Signapurkar, Sonal Yadav, Pramila Pharmacoeconomic Analysis of Fixed-Dose Combinations of Proton Pump Inhibitors Available in India |
title | Pharmacoeconomic Analysis of Fixed-Dose Combinations of Proton Pump Inhibitors Available in India |
title_full | Pharmacoeconomic Analysis of Fixed-Dose Combinations of Proton Pump Inhibitors Available in India |
title_fullStr | Pharmacoeconomic Analysis of Fixed-Dose Combinations of Proton Pump Inhibitors Available in India |
title_full_unstemmed | Pharmacoeconomic Analysis of Fixed-Dose Combinations of Proton Pump Inhibitors Available in India |
title_short | Pharmacoeconomic Analysis of Fixed-Dose Combinations of Proton Pump Inhibitors Available in India |
title_sort | pharmacoeconomic analysis of fixed-dose combinations of proton pump inhibitors available in india |
topic | Emergency Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10098438/ https://www.ncbi.nlm.nih.gov/pubmed/37065352 http://dx.doi.org/10.7759/cureus.36112 |
work_keys_str_mv | AT deolekarpradnya pharmacoeconomicanalysisoffixeddosecombinationsofprotonpumpinhibitorsavailableinindia AT vivekkavita pharmacoeconomicanalysisoffixeddosecombinationsofprotonpumpinhibitorsavailableinindia AT ghoshsouvik pharmacoeconomicanalysisoffixeddosecombinationsofprotonpumpinhibitorsavailableinindia AT naseemazra pharmacoeconomicanalysisoffixeddosecombinationsofprotonpumpinhibitorsavailableinindia AT srivathsanmayakalyani pharmacoeconomicanalysisoffixeddosecombinationsofprotonpumpinhibitorsavailableinindia AT raiviveks pharmacoeconomicanalysisoffixeddosecombinationsofprotonpumpinhibitorsavailableinindia AT signapurkarsonal pharmacoeconomicanalysisoffixeddosecombinationsofprotonpumpinhibitorsavailableinindia AT yadavpramila pharmacoeconomicanalysisoffixeddosecombinationsofprotonpumpinhibitorsavailableinindia |